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The class 1 protein of Neisseria meningitidis is an important component of candidate outer membrane
vaccines against meningococcal meningitis. This porin protein contains two variable regions which determine
subtype specificity and provide binding sites for bactericidal monoclonal antibodies. To determine the
contribution of each of these variable regions in the induction of bactericidal antibodies, a set of isogenic strains
differing only in their class 1 epitopes was constructed. This was done by transformation of meningococcal
strain H44/76 with cloned class 1 genes and selection of the desired epitope combinations in a colony blot with
subtype-specific monoclonal antibodies. When used for the immunization of mice, outer membrane complexes
induced bactericidal antibodies only against meningococcal strains sharing at least one of their class 1 epitopes.
The results demonstrate that the P1.2 and P1.16 epitopes, normally located in the fourth exposed loop of the
protein, efficiently induce bactericidal antibodies independently of the particular sequence in the first variable
region. The P1.5 and P1.7 epitopes, normally located in the first exposed loop, were found to induce lower
bactericidal titers. Hybrid class 1 outer membrane proteins were constructed by inserting oligonucleotides
encoding the P1.7 and P1.16 epitopes into the porA gene. In this way, we obtained a set of strains which carry
the P1.5 epitope in loop 1, P1.2 in loop 4, and P1.7 and P1.16 (separately or in combination) in either loop 5
or loop 6. The additional epitopes were found to be exposed at the cell surface. Outer membrane complexes
from several of these strains were found to induce a bactericidal response in mice against the inserted epitopes.
These results demonstrate that it is feasible to construct meningococcal strains carrying multivalent class 1
proteins in which multiple subtype-specific epitopes are present in different cell surface-exposed loops.
Neisseria meningitidis is a human pathogen of worldwide
significance. Vaccines containing the capsular polysaccha-
ride provide limited protection against infection caused by
strains of serogroupsA and C. Immunity is, however, of short
duration, and infants fail to respond. Polysaccharide vaccines
do not induce protection against group B organisms, the
predominant cause of infection in many countries, because
of the poor immunogenicity of the group B polysaccharide in
humans. Therefore, vaccines based on outer membrane
proteins are currently being evaluated for their efficacy in
preventing meningococcal disease (11, 36). Recent field trials
in humans with such vaccines have demonstrated at least
partial protection against group B infection (4, 7).
The porins are among the most abundant proteins present
in the meningococcal outer membrane, and unlike several
other major surface antigens, they do not undergo antigenic
drift during infection. They function by creating pores
through which small hydrophilic solutes can pass in a
diffusion-like process. All meningococcal strains contain
either a class 2 or class 3 protein, both of which form pores
with anion selectivity (5). The class 1 protein is expressed by
almost all meningococcal isolates, although there is variation
in the level of expression (24). It forms pores which display
cationic selectivity (30). Antigenic diversity of class 2/3 and
class 1 proteins forms the basis for division of meningococ-
cal strains into different serotypes and subtypes, respec-
tively (12).
Monoclonal antibodies (MAbs) directed against subtype-
specific epitopes on class 1 protein have been shown to be
* Corresponding author.
particularly effective in bactericidal assays and in conferring
protection in an animal model (27, 28). Also, after immuni-
zation of mice with outer membrane complexes (OMCs),
bactericidal activity is mainly directed against this protein
(32). Thus, OMCs containing class 1 protein are serious
candidates for a meningococcal vaccine. A major problem
with this approach, i.e., the limited range of protection,
might be overcome by constructing a strain expressing
multiple class 1 proteins of different subtypes and lacking
other, nonprotective outer membrane proteins (32).
Sequence comparison of different class 1 subtypes has
shown that the major variation is confined to two discrete
regions (17, 18). The epitopes recognized by bactericidal
MAbs were localized to either one of these variable domains
(18, 31). In a model for the topology of neisserial porins,
these sequences are located in the first and fourth surface-
exposed loops (31). In the present study, we have investi-
gated the extent to which these two regions act indepen-
dently in the generation of bactericidal antibodies. For this
purpose, a set of isogenic strains differing only in their
combination of class 1 epitopes was constructed through
transformation. In the same way, strains containing inser-
tions in other, normally more conserved loops were also
made. These newly inserted epitopes were found to be
exposed at the cell surface, demonstrating that this is a
feasible way to construct strains with multivalent class 1
proteins.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Table 1 lists the
meningococcal strains used in this study. They were grown
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TABLE 1. Meningococcal strains
Strain Relevant characteristics Reference
H44/76 B:15:P1.7,16 13
2996 B:2b:P1.5,2 25
MC50 C:nt:P1.16 3
HIII5 Class 3-deficient mutant of H44/76 30
1-2 HIII5 with second porA gene 32
TR52 H44/76 transformed with pCO14 to This study
P1.5,2
TR72 H44/76 transformed with pCO3 to This study
P1.7,2
TR516 TR52 transformed with pCO6 to This study
P1.5,16
TR7216 TR72 with P1.16 epitope inserted This study
in loop 5
K007 TR52 with P1.7 epitope inserted in This study
loop 5
K016 TR52 with P1.16 epitope inserted This study
in loop 5
K716 TR52 with P1.7 and P1.16 epitopes This study
inserted in loop 5
J007 TR52 with P1.7 epitope inserted in This study
loop 6
J016 TR52 with P1.16 epitope inserted This study
in loop 6
J716 TR52 with P1.7 and P1.16 epitopes This study
inserted in loop 6
overnight at 37°C on GC medium base (Difco) plates supple-
mented with IsoVitaleX in a humid atmosphere containing
5% CO2. The medium used for growth in liquid culture
contained, per liter, 1.3 g of glutamic acid, 0.02 g of cysteine,
2.5 g of Na2HP04 2H20, 0.09 g of KCl, 6.0 g of NaCl,
1.25 g of NH4C1, 0.6 g of MgSO4- 7H20, 5.0 g of glucose,
and 2.0 g of yeast extract (pH 7.8) and was filter sterilized.
Escherichia coli NM522, used for the propagation of plas-
mids, was grown in LB medium (26) containing ampicillin
(100 ug/Iml) and, when necessary, 1 mM isopropylthiogalac-
topyranoside (IPTG).
Recombinant DNA techniques. Plasmids were constructed
by using standard recombinant DNA techniques (26). Sticky
ends were made blunt by incubation with T4 DNA poly-
merase, as prescribed by the manufacturer (Boehringer
Mannheim). Restriction fragments were purified from low-
melting-point agarose gels (NuSieve GTG agarose; FMC
BioProducts). The polymerase chain reaction (PCR) was
performed for 30 cycles of 1 min at 95°C, 1.5 min at 42°C, 1
min at 55°C, and 1 min at 72°C on a Bio-Med Thermocycle
60. The PCR buffer (lOx) contained 100 mM Tris. HCl (pH
8.3), 500 mM KCl, 15 mM MgCl2, and 0.1% gelatin. Taq
polymerase was purchased from Perkin-Elmer Cetus.
Construction of plasmids. The plasmid vector used for all
constructs was pTZ19R (21). Cloning and sequencing of the
porA gene from strains 2996, H44/76, and MC50 have been
described previously (3, 18, 31). A diagram of the porA
plasmids used is shown in Fig. 1. Plasmids pCO2 and pCO3
both contain a 1.9-kb EcoRI fragment with the C-terminal
part of the porA gene of strain 2996 (subtype P1.5,2) in
opposite orientations. A 29-bp deletion in the polylinker of
pCO3 was made by digesting with SalI and EcoRI, flushing
the sticky ends with T4 DNA polymerase, and religating.
This resulted in plasmid pCO20, which has an in-frame
fusion between the lacZ' gene and the porA gene starting
from residue 100 and a now unique KpnI site located in the
part of the gene encoding loop 5. The complete strain 2996
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FIG. 1. Schematic representation of the porA gene. Shaded
areas indicate the eight surface-exposed regions. Restriction frag-
ments carried by the various plasmids used in this study are
indicated below, showing what portion of theporA gene is contained
in each. Plasmids pCO2 and pCO3 contain the same fragment but in
opposite orientations. Restriction sites indicated are for EcoRI (E),
KpnI (K), and XbaI (X).
porA gene is present in plasmid pCO14 on a 2.8-kb XbaI-
EcoRI fragment. In pCO6, the C-terminal part ofporA from
strain MC50 (subtype P1.16) is contained on a 1.3-kb EcoRI-
XbaI fragment.
For the insertion of additional epitopes in loop 5, synthetic
complementary oligonucleotides of 39 bp were made (Fig.
2). Annealing of the complementary strands resulted in
KApnI-compatible sticky ends. Plasmid pCO20 was digested
with KpnI, ligated to a 30-fold molar excess of nonphosphor-
ylated double-stranded oligonucleotide, heated to 65°C and
cooled slowly to room temperature to melt out the nonco-
valently linked strands, redigested with KpnI (insertion of
the oligonucleotide removes the KpnI site), and transformed
KpnI site in loop 5:
A K G T D P
GCC.AAA.GGT.ACC .GAT.CCC
KpnI site in loop 6:
A D K T K N
GCC.GAC.AAA ACC .AAA .AAC
A D G T K N
GCC .GAC .GGT.ACC.AAA.AAC
P1.7 (KpnI sticky ends):
N G G A S G Q V K V T
G AAC.GGC.GGC.GCC.TCT.GGC.CAA.GTT.AAA.GTT..ACTAGTAC
CATGC TTG.CCG.CCG.CGG.AGA.CCG.GTT.CAA.TTT.CAA.TGA T
P1.16 (KpnI sticky ends):
Y T K D T N N N L T L
G TAT.ACC.AAA.GAC.ACC.AAC.AAC.AAC .TTG.ACC.TTG AGTAC
CATGC ATA.TGG.TTT.C .TGG.TTIG.TTG.T'TG.AAC.TGG.AAC T
P1.16 (SpeI sticky ends):
Y T K D T N N N L T L
CTAGC TAT.ACC .AAA.GAC .ACC.AAC .AAC .AAC .TTG.ACC . TTGT
G ATA. TGG.TT .CTG. T.TG.T.TM. AAC. TGG. AAC AGATC
FIG. 2. Oligonucleotides used for the insertion of additional
epitopes. Double-stranded oligonucleotides containing KpnI-com-
patible sticky ends and the sequences of the previously identified
P1.7 and P1.16 epitopes (18) were synthesized and ligated into the
KpnI site in loop 5 and into the KpnI site introduced as indicated
into loop 6 by PCR mutagenesis. Insertion of either oligonucleotide
removes the Kpnl site; insertion of the P1.7 oligonucleotide intro-
duces a SpeI site (underlined), which was subsequently used for
insertion of a P1.16 oligonucleotide with SpeI-compatible sticky
ends.
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FIG. 3. Binding of MAbs to whole cells of derivatives of H44/76
expressing hybrid class 1 proteins. The extinction at 450 nm is
indicated for each strain with four subtype-specific MAbs.
to E. coli NM522. To test whether the insertion was present
in the correct orientation, transformants were grown in the
presence of IPTG to induce the LacZ-PorA fusion protein.
The resulting cell lysates were tested by Western blotting
(immunoblotting) with MAbs specific for P1.2 and the in-
serted epitope P1.7 or P1.16. For the insertion of both
epitopes, a pCO20 derivative with an inserted P1.7 oligonu-
cleotide was digested with SpeI and ligated in the same way
to a P1.16 oligonucleotide with SpeI sticky ends (Fig. 2).
This results in a tandem insertion of both oligonucleotides.
The presence of both P1.7 and P1.16 epitopes (in addition to
P1.2) was again verified by Western blotting.
Insertions in loop 6 were made in exactly the same way,
starting from plasmid pPH204, which has a KpnI site located
in the part ofporA encoding loop 6 (Fig. 2). This plasmid was
derived from pCO20 in the following way. First, the KpnI
site in loop 5 was removed by digestion with KpnI, flushing
with T4 DNA polymerase, and insertion of a 10-bp nonphos-
phorylatedBamHI linker (5'-CGGGATCCCG-3'). Second, a
K:inI site was introduced in loop 6 by PCR mutagenesis.
PCR products were generated with primer mpl (5'-GGA
GGTACCAAAAACAGTACGACCGAAATT-3') plus M13
reverse sequencing primer (5'-CAGGAAACAGCTATGAC-
3') on pCO2, consisting of the C-terminal part ofporA, and
with mp2 (5'-GGAGGTACCGTCGGCATTlICAGACAA
ATCCAA-3') plus M13 reverse sequencing primer on pCO20
with the BamHI linker insertion, consisting of the N-termi-
nal part. These PCR products were then digested with KpnI
(underlined sequence) and used to reassemble the 1.9-kb
EcoRI fragment. The resulting plasmid, pPH204, differs
from pCO20 by the replacement of the KpnI site in loop 5 by
a BamHI site and the insertion of a new KpnI site in loop 6.
Transformation of meningococci. Allelic replacement of
the meningococcalporA gene with constructs made in E. coli
was done by transformation with undigested plasmid DNA
as described previously (32). Transformants expressing the
selected epitope of the incoming porA gene were identified
by using a colony blot procedure (32) with one of the
following MAbs (18, 31): MN16C13F4 (P1.2), MN22A9.19
(P1.5), MN14C11.6 (P1.7), and MN5C11G (P1.16). Expres-
sion of class 1 epitopes on whole cells of the constructed
strains was quantitated by enzyme-linked immunosorbent
assay (ELISA) (1). The plates were read at 450 nm on a
model EL312e Bio-Kinetics reader (Bio-Tek Instruments).
Immunological methods. OMCs were isolated from menin-
gococci grown in liquid medium by sarcosyl extraction as
described previously (31). The protein composition was
analyzed by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) (16). Western immunoblotting of
cell lysates and OMCs with subtype-specific MAbs was done
as described elsewhere (23). For immunization, outbred 14-
to 17-g female NIH mice were injected subcutaneously with
2.5 ,ug of OMC protein in saline and 0.5 mg of AlPO4 in a
volume of 0.5 ml. This procedure was repeated after 4
weeks, and the animals were bled at week 6. Bactericidal
activity of the sera was determined by using human comple-
ment from an immunoglobulin-deficient patient (22).
RESULTS
Construction of isogenic meningococcal strains expressing
hybrid class 1 outer membrane proteins. To investigate
further the role of the class 1 variable regions in the
induction of bactericidal antibodies by OMCs, allelic re-
placement by transformation was used to construct a set of
isogenic derivatives of strain H44/76 differing only in the
porA gene. Transformants were found at a frequency of
approximately 10-3 to 10-4 when plasmid DNA was used,
which is sufficiently high for direct identification in a colony
blot with subtype-specific MAbs. The plasmids used for
transformation carry different fragments ofporA alleles and
are shown in Fig. 1. First, transformation with plasmids
pCO14 and pCO3 resulted in strains TR52 and TR72 (Table
1), in which the 7,16 allele has been changed to 5,2 and 7,2,
respectively. Strain TR52 was subsequently transformed to
5,16 with plasmid pCO6. In this way, we obtained deriva-
tives of H44/76 which expressed each of the four epitope
combinations P1.7,16, P1.5,2, P1.7,2, and P1.5,16. Expres-
TABLE 2. Bactericidal titers of mouse antisera against OMCs containing hybrid class 1 proteins
Bactericidal titer against test straine:
Immunizing OMC
2996 (2b:P1.5,2) MC50 (nt:P1.16) TR52 (15:P1.5,2) H44t76 (15:P1.7,16)
H44/76 (15:P1.7,16) <1:2 >1:2,048 1:256 >1:2,048
2996 (2b:P1.5,2) >1:2,048 <1:2 >1:2,048 1:8
1-2 (-:P1.7,16,5,2) >1:2,048 1:1,024 >1:2,048 >1:2,048
TR52 (15:P1.5,2) >1:2,048 <1:2 >1:2,048 <1:2
TR72 (15:P1.7,2) 1:2,048 <1:2 >1:2,048 1:256
TR516 (15:P1.5,16) 1:128 1:512 1:256 1:1,024
TR7216 (15:P1.7,2,16) 1:2,048 <1:2 >1:2,048 1:512
Control <1:2 <1:2 1:32 <1:2
a Mice were immunized with 2.5 pg of OMC protein. For each immunization, eight mice were used and their sera were pooled. Bactericidal titers are shown
as the highest serum dilution that killed half of the cells of the indicated test strain.
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FIG. 4. Insertion of additional epitopes into loops 5 and 6 of class 1 protein. (A) Topology model for strain 2996 (adapted from reference
31). (B) The various insertions into ioops 5 and 6 of this protein. The residues marked with asterisks represent points of insertion. Residues
shown in boldface represent the P1.5, P1.2, P1.7, and P1.16 epitopes as identified previously (18, 31).
sion of these epitope combinations was verified with a
whole-cell ELISA (Fig. 3).
In addition, a strain expressing a P1.7,2,16 epitope com-
bination was obtained by transformation with a derivative of
pCO2O in which a 39-bp oligonucleotide has been inserted
into the KjpnI site, which is located in the part of the porA
gene encoding loop 5 (Fig. 2). Transformation of TR72 with
this plasmid and selection with the P1.16-specific M4Ab
resulted in strain TR7216, expressing the P1.16 epitope as a
13-amino-acid residue insertion into loop 5, in addition to the
P1.7 and P1.2 epitopes in loops 1 and 4, respectively.
Although the P1.16-specific MIAb was able to bind to this
protein at the cell surface, the whole-cell ELISA values
obtained were considerably lower than those for a normal
P1.16 strain (Fig. 3). Isolation of OMCs and analysis by
SDS-PAGE demonstrated that all hybrid class 1 proteins
thus obtained were present in the outer membrane in normal
amounts (not shown). Neither H44/76 nor any other one of
this particular set of derivatives expressed any cpa gene in a
significant amount.
Immunization with OMCs containing hybrid class 1 pro-
teilns. Mice were immunized with 0MG preparations from
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FIG. 5. SDS-PAGE analysis of OMCs from strains with addi-
tional class 1 epitopes. Shown are TR52 (lane 1), H44/76 (lane 2),
K007 (lane 3), K016s (lane 4), K716 (lane 5), J007 (lane 6), J016 (lane
7), and J716 (lane 8). Molecular mass markers of 94, 67, 43, 30, 20.1,
and 14.4 kDa are present in the leftmost lane.
the set of strains described above and from 2996 (the P1.5,2
reference strain) and the bivalent vaccine strain 1-2 (32). The
last is a class 3 protein-deficient derivative of H44/76 that
expresses two different class 1 proteins, i.e., of subtypes
P1.7,16 and P1.5,2 (32); it was included as a positive control
for class 1-specific bactericidal activity. The other strains
used for this immunization differ only in class 1 protein; the
other major OMC component, class 3 protein of serotype 15,
was shared among them. The resulting antisera were tested
for bactericidal activity against strains H44/76, TR52, 2996,
and MC50 (Table 2). High bactericidal activity was found
only when the immunizing OMCs and the test strain shared
at least one of their class 1 variable regions. The only
exception was strain TR52 with the antisera induced by
H44/76 OMCs; this strain was also the only one that showed
some bactericidal activity with the control sera. In all cases,
higher levels of bactericidal antibodies were induced by the
second than by the first variable region. This difference is
more pronounced for the P1.5/P1.2 than for the P1.7/P1.16
comparison. Strain TR7216 produced bactericidal titers sim-
ilar to those produced by strain TR72; this also occurred
when MC50 was used as the test strain. Apparently, the
P1.16 epitope in loop 5 is not capable of inducing bactericidal
antibodies against P1.16 in its normal position in loop 4.
Insertion of additional epitopes into surface-exposed loops of
class 1 protein. The topology models for neisserial porins
predict eight surface-exposed loops (31). In class 1 protein,
the protective epitopes are located in loops 1 and 4. In an
attempt to construct meningococcal strains carrying more
than the normal two subtype determinants, we inserted
additional epitopes into loops 5 and 6 in the following way.
Plasmid pCO20 carries a 1.9-kb fragment encoding the
C-terminal part of theporA gene from strain 2996, starting at
residue 100 and fused in frame to the lacZ' gene (see
Materials and Methods for details of plasmid constructions).
Oligonucleotides with KpnI-compatible sticky ends were
inserted into the unique KjpnI site of this plasmid, a site
located in the part of the gene encoding loop 5 (Fig. 2). For
insertion into loop 6, site-specific mutagenesis was used to
construct plasmid pPH204, with the KpnI site located in the
part encoding the apex of loop 6 instead of loop 5 (Fig. 2).
The constructs were subsequently used for transformation of
strain TR52, with selection for one of the newly inserted
epitopes in a colony blot. In this way, we obtained a set of
strains which carry the P1.5 epitope in loop 1, P1.2 in loop 4,
and P1.7 and P1.16 (separately or in combination) in either
loop 5 or loop 6 (Table 1 and Fig. 4). The insertions had a
length of either 13 or 26 residues. All strains showed a
TABLE 3. Bactericidal titers of mouse antisera against OMCs
containing additional epitopes in class 1 protein
Bactericidal titer against test straina:
Immunizing OMC
H44/76 (15:P1.7,16) 2996 (2b:P1.5,2)
H44/76 (15:P1.7,16) > 1:2,048 < 1:2
TR52 (15:P1.5,2) 1:128 >1:2,048
K007 (15:P1.5,2,7) 1:512 >1:2,048
K016s (15:P1.5,2,16) 1:1,024 1:2,048
K716 (15:P1.5,2,7,16) 1:256 1:2,048
J007 (15:P1.5,2,7) 1:256 >1:2,048
J016 (15:P1.5,2,16) 1:512 >1:2,048
J716 (15:P1.5,2,7,16) 1:2,048 >1:2,048
Control <1:2 <1:2
a Mice were immunized with 2.5 ,ug of OMC protein. For each immuniza-
tion, eight mice were used and their sera were pooled. Bactericidal titers are
shown as the highest serum dilution that killed half of the cells of the indicated
test strain. In a duplicate experiment with the same sera, titers did not differ
from those shown by more than a factor of 2.
normal amount of class 1 protein in the outer membrane, as
demonstrated by SDS-PAGE of OMCs (Fig. 5). In a whole-
cell ELISA, the level of binding of P1.5- and P1.2-specific
MAbs to the cell surface was the same as with the parent
strain TR52 (Fig. 6). Compared with strain H44/76, the P1.7
and P1.16 epitopes gave a variable amount of binding depen-
dent on the particular construct (Fig. 6). Surface exposure of
all additional epitopes could be demonstrated, although
binding to P1.16 in strain J716 was very weak. When the
transformant containing an insertion of P1.16 in loop 5 was
streaked for purification, the colony blot also showed a
single aberrant colony with more intense MAb binding. This
variant was also isolated. In the whole-cell ELISA, an
almost twofold difference in binding to P1.16 was found
between these two variants, termed K016z and K016s, for
weak and strong reactivity, respectively (Fig. 6). On SDS-
PAGE, these two variants were identical with respect to the
level of class 1 expression and its electrophoretic mobility
(not shown).
Immunization with OMCs containing additional epitopes in
class 1 protein. Mice were immunized with OMC prepara-
tions from the set of strains described above, including the
parent strains H44/76 and TR52. These OMCs differ only in
class 1 protein, with the exception of J716, which also
produces a class 5 protein (Fig. 5). The resulting antisera
were tested for bactericidal activity against strains H44/76
and 2996 (Table 3). The insertion of epitopes in loops 5 and
6 of TR52 resulted in a significant increase in bactericidal
titer against H44/76 with several constructs, in particular
K016s and J716, which almost reached the level of H44/76
itself. Bactericidal titers against strain 2996 remained high in
all cases, showing that the immunogenicity of loops 1 and 4
is not impaired. Since the test strains used do not express
significant amounts of class 5 protein, its presence in J716
cannot influence the outcome of the bactericidal assay.
DISCUSSION
In a previous study, we have presented a model for the
topology of class 1 protein and other neisserial porins (31). It
predicted eight surface-exposed loops on a 16-stranded
1-sheet transmembrane structure. Similar models have been
proposed for PhoE protein and other porins from E. coli (29).
The recent determination of high-resolution three-dimen-
sional structures for the porin of Rhodobacter capsulatus
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FIG. 6. Binding of MAbs to whole cells of strains carrying additional epitopes in loop 5 (A) or loop 6 (B). For each strain, the extinction
at 450 nm is plotted against the MAb dilution used.
(34) and the OmpF and PhoE porins of E. coli (8) has
confirmed the validity of these models and suggests the
existence of a porin fold common to many of these proteins
from different bacteria, which show only little sequence
homology (14). The present study has confirmed the surface
exposure of loops 5 and 6 of class 1 protein, since epitopes
inserted here are accessible to MAbs in whole cells. Surface
exposure has previously been demonstrated for loops 1 and
4 (31).
After immunization of mice with OMCs, bactericidal
activity is much higher against strains with the same class 1
protein than against those with only the same class 3 protein
(Table 2) (32). A plausible explanation for this difference is
provided by our model, which shows that the length of the
surface-exposed loops is much longer in class 1 protein than
in other neisserial porins, including the class 3 protein, for
which sequence information has only recently become avail-
able (6). One can thus envisage that these loops in class 1
protein are more immunogenic and/or more accessible to
antibodies once formed.
Sequence diversity among different class 1 subtypes is
mainly confined to loops 1 and 4 (31). In addition to
completely different versions of these variable regions, se-
quence heterogeneity of particular subtypes has also been
observed (19, 20). Sometimes the same variable regions are
found in different combinations in different strains (9, 17,
18). These observations have to be taken into account when
the construction of a multivalent vaccine based on the class
1 protein is considered (32). The results presented in this
study are important in this context. They show that changing
one variable region still allows the correct antibodies to be
formed against the other one; in this respect, these two loops
thus behave to a large extent independently of each other. In
addition, we have demonstrated that bactericidal activity is
higher against loop 4 than against loop 1.
We chose loops 5 and 6 of class 1 protein for the insertion
of additional epitopes because in the homologous gonococ-
cal porins PIA and PIB, they can bind bactericidal antibodies
(31). Also, in class 2 and 3 proteins, these loops show
sequence diversity among different serotypes, albeit less
pronounced than in the variable regions of class 1 protein
(10, 33, 35). The surface exposure of the newly inserted
epitopes shows that this is a valid approach for the construc-
tion of multivalent class 1 proteins. In a similar way, the
PhoE and LamB outer membrane proteins of E. coli have
been used as carriers of foreign antigenic determinants (2,
15). A different aspect of our work is the need to insert
additional epitopes without disturbing the existing ones. This
is indeed possible for loops 5 and 6, because (i) these regions
are not very important for the induction of bactericidal
antibodies, as evidenced by the low or absent bactericidal
activity when the immunizing and test strains share loops 5
A
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and 6 but have different variable regions, (ii) the insertions
do not show any effect on the accessibility of loops 1 and 4
to their MAbs, and (iii) the bactericidal response against
loops 1 and 4 remains unaffected when insertions are present
in loop 5 or 6.
Induction of bactericidal antibodies by additional epitopes
is one of the goals of this approach. It was initially expected
that this would require the construction of strains showing a
level of MAb binding to whole cells similar to the wild-type
level. With the P1.7 epitope, this was indeed found for all
constructs; with P1.16, binding was more variable. Appar-
ently, the latter is more dependent on a particular configu-
ration. However, induction of bactericidal antibodies is not
correlated to MAb binding in the whole-cell ELISA; in strain
J716, P1.16 binding is very low and P1.7 binding is not as
high as in some other constructs, whereas this strain gave
the highest bactericidal titer. Of course, the affinity of a
particular MAb for its epitope is probably dependent not
only on surface exposure per se but also on the particular
conformation of the inserted sequence in a construct; this
effect is likely to be different when the induction of antibod-
ies, i.e., immunogenicity instead of antigenicity, is consid-
ered. Since the ability of the constructs to induce bacteri-
cidal antibodies can apparently not be predicted from the
level of MAb binding, empirical construction of the optimal
insertion for each individual epitope will be necessary.
Insertion of P1. 16 in loop 5 resulted in bactericidal activity
against this epitope with strain K016s but not with strain
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TR7216. In the former strain, a spontaneous variant with a
twofold-higher level of P1.16 MAb binding was accidentally
obtained and used in the immunization. The nature of this
mutation is not known, but it is a likely cause for the
observed difference between TR7216 and K016s in bacteri-
cidal activity. Since a comparison of K016z and K016s
showed no alteration in binding of lipopolysaccharide (LPS)-
specific MAbs (not shown) or of P1.5/2-specific MAbs (Fig.
6), a point mutation specifically affecting the P1.16 epitope is
the most likely explanation.
As this work has demonstrated, insertion of additional
sequences of up to 26 residues in the surface-exposed loops
5 and 6 of class 1 protein while maintaining the immunoge-
nicity of loops 1 and 4 is possible. In addition to inserting
meningococcal subtype epitopes, this approach can also be
used to insert other useful sequences in class 1 protein
without distorting its immunogenicity. For instance, inser-
tion of cysteine residues could allow chemical conjugation of
LPS-derived oligosaccharides to a predetermined site at the
cell surface-exposed part of the protein.
In the course of this work, transformation of meningo-
cocci with cloned porA genes was found to be very easy.
Transformation frequencies of 10'- to 10-4 were routinely
obtained, making direct identification in a colony blot pos-
sible without the need for use of an antibiotic resistance
marker. Transformants thus obtained always resulted from
allelic replacement. This high frequency suggests that trans-
formation could also allow strains to change their subtype in
B monodonda-P12
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vivo. Indeed, sequence comparison of differentporA alleles
has shown a mosaic composition, reminiscent of exchange of
sequence blocks between different strains (9).
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